𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination chemotherapy with carboplatin and bleomycin for advanced and recurrent head and neck cancer: A phase II study

✍ Scribed by Jose L. Gonzalez-Vela; Lawrence Panasci; Martin Black; Michael Pollak; Richard Margolese

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
143 KB
Volume
39
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Carboplatin is a platinum analogue with activity reported in head and neck cancer. We conducted a phase II trial with 14 patients who had recurrent head and neck cancer. They were treated with carboplatin 300 mg/m2 intravenously (I.V.) and bleomycin 30 units I.V. every 4 weeks. No responses were observed in this group of patients. Dose intensity of carboplatin administration may be an important determinant of response.

πŸ“œ SIMILAR VOLUMES

Phase I/II study of S-1 combined with ca
Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy
✍ Akihito Watanabe; Masanobu Taniguchi; Tetsuro Yamashita; Michihiro Ueda; Tatsuya πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## Abstract ## Background. The aims of this study were to determine the recommended dose (RD) in combination chemotherapy of S‐1 and carboplatin in recurrent and/or metastatic head and neck cancer (phase I) and to examine response rate and toxicities at RD (phase II). ## Methods. S‐1 was given o

Phase 1 trial of combined chemotherapy a
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer
✍ Sharon Spencer; Richard Wheeler; Glenn Peters; Ruby Meredith; Sam Beenken; Lisle πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 2 views

## Abstract ## Background. The management of recurrent unresectable head and neck cancer remains a challenging problem. Based on the circadian rhythm concept, we sought to determine the maximum tolerated dose (MTD) of infusional 5‐flourouracil (5‐FU), hydroxyurea (HU), and reirradiation (RT). ##

Multidrug chemotherapy using bleomycin,
Multidrug chemotherapy using bleomycin, methotrexate, and cisplatin combined with radical radiotherapy in advanced head and neck cancer
✍ Dr. J. Zidan; A. Kuten; Y. Cohen; E. Robinson πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 266 KB πŸ‘ 2 views

Thirty-one patients with Stage III-IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete r

Chemotherapy of head and neck cancer: Co
Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin
✍ Wittes, Robert E. ;Spiro, Ronald H. ;Shah, Jatin ;Gerold, Frank P. ;Koven, Berna πŸ“‚ Article πŸ“… 1977 πŸ› John Wiley and Sons 🌐 English βš– 470 KB πŸ‘ 1 views

## Abstract A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50

A phase II study of piritrexim in combin
A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer
✍ Everett E. Vokes; Isaiah W. Dimery; Charlotte D. Jacobs; Daniel Karp; Arturo Mol πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 468 KB πŸ‘ 2 views

Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day